8 March 2023
MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)
Pilot Testing Agreement for PFAS Remediation at Municipal Solid Waste Landfill
MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company, is pleased to announce that it has entered into a second pilot testing agreement for treatment of PFAS in landfill leachate in the United States with a new customer.
The system includes a MYCELX fully containerized, mobile PFAS remediation system with MYCELX infused cartridge filtration and Performer™ media and will be utilized on-site for treatment of PFAS contaminated leachate from a municipal solid waste landfill. The pilot is expected to successfully demonstrate the ability of the proprietary MYCELX technology, and completely remove all identified PFAS chemicals to non-detectable concentrations in a single pass.
Connie Mixon, CEO, commented:
"We are pleased to announce the signing of a second pilot testing agreement for PFAS remediation in the United States so far this year. We are firmly focused on expanding our footprint in the PFAS remediation market in 2023, and this is further evidence of us delivering on this objective."
For further information, please contact:
| MYCELX Technologies Corporation Connie Mixon, CEO Kim Slayton, CFO
|
Tel: +1 888 306 6843 |
| Canaccord Genuity Limited (Nomad and Sole Broker) Henry Fitzgerald-O'Connor Gordon Hamilton
|
Tel: +44 20 7523 8000 |
| Celicourt Communications (Financial PR) Mark Antelme Jimmy Lea |
Tel: +44 20 8434 2754 |
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
